SARS-CoV-2 mutations complicate killer T cell immune response, study shows
Researchers have found that mutations in SARS-CoV-2 T cell epitopes enable the virus to evade the immune response of killer T cells.
List view / Grid view
Researchers have found that mutations in SARS-CoV-2 T cell epitopes enable the virus to evade the immune response of killer T cells.
As laboratories face the challenge of screening many samples for SARS-CoV-2, lab managers have turned to the use of automation to address key concerns.
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
Researchers have shown that administering a urinary tract infection vaccine directly to the bladders of mice helped them to effectively fight bacteria.
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.
A peptide administered to ferrets protected them from SARS-CoV-2 viral transmission when housed with infected ferrets.
A new vaccine is effective at preventing opioid overdose from fentanyl and carfentanil in rodents, according to a new study.
A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.